Abstract
A novel series of 2-(m-Chlorobenzyl)-4-substituted-1, 1, 3-trioxo-2H,4H-pyrazolo[4, 5-e][1, 2, 4] thiadiazines (7a-k) were synthesized, and evaluated for their anti-HIV replication in MT-4 cell cultures. Compound (7a) showed activity against HIV-1-induced cytopathicity, with an EC50 value of 45.6 μM, but none of the compounds exhibited inhibitory activity against HIV-2.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arranz, M. E., Vega, S., and Diaz, J. A., Synthesis of Hetero [1,2,4]thiadiazine 1,1-Dioxides.Heterocycles, 45, 1767–1774 (1997).
Arranz M. E., Diaz, J. A., Ingate, S. T., Witvrouw, M., Pannecouque, C., Balzarini, J., De Clercq, E., and Vega, S., Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication.J. Med. Chem., 41, 4109–4117 (1998).
Arranz, M. E., Diaz, J. A., Ingate, S. T., Witvrouw, M., Pannecouque, C., Balzarini, J., De Clerq, E., and Vega, S., Synthesis and anti-HIV activity of 1,1,3-trioxo-2H,4H-thieno [3,4-e] [1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors.Bioorg. Med. Chem., 7, 2811–2822 (1999).
Arranz, M. E., Diaz, J. A., Vega, S., Campos-Toimil, M., Orallo, F., Cardelus, I., Llenas, J., and Fernandez, A. G., Synthesis and pharmacological evaluation of 2, 3-dihydro-3-oxo-4H-thieno [3, 4-e][1, 2, 4]thiadiazine 1, 1-dioxidesas voltage-dependent calcium channel blockers.Eur. J. Med. Chem., 35, 751–759 (2000).
Das, K., Lewi, P. J., Hughes, S. H., and Arnold, E., Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.Prog. Biophys. Mol. Biol., 88, 209–231 (2005).
De Clercq, E., Recent highlights in the development of new antiviral drugs.Curr Opin Microbiol., 8, 552–560 (2005).
Joncckheere, H., Anne, J., and De Clercq, E., The HIV-1 reverse transcription (RT) process as target for RT inhibitors.Med. Res. Rev., 20, 129–154 (2000).
Martinez, A., Gil, C., Abasolo, M. I., Castro, A., Bruno, A. M., Perez, C., Prieto, C., and Otero, J., Benzothiadiazine dioxide dibenzyl derivatives as potent human cytomegalovirus inhibitors: Synthesis and comparative molecular field analysis.J. Med. Chem., 43, 3218–3225 (2000a).
Martinez, A., Gil, C., Perez, C., Castro, A., Prieto, C., Otero, J., Andrei, G., Snoeck, R., Balzarini, J., and De Clercq E., Nucleoside human cytomegalovirus inhibitors: Synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives.J. Med. Chem., 43, 3267–3273 (2000b).
Patani, G. P. and LaVoie, E. J., Bioisosterism: A rational approach in drug design.Chem. Rev., 96, 3147–3176 (1996).
Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., and De Clercq, E., Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.J. Virol. Methods., 20, 309–321 (1988).
Schaefer, W., Gunar Friebe, W., Leinert, H., Mertens, A., Poll, T., Vonder Saal, W., Zilch, H., Nuber, B., and L. Ziegler, M., Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and x-ray structure investigations.J. Med. Chem., 36, 726–732 (1993).
Witvrouw, M., Arranz, M. E., Pannecouque, C., Declerq, R., Jonckheere, H., Schmit, J. C., Vandamme, A. M., Dia, J. A., Ingate, S. E., Desmyter, J., Esnouf, E., Meervelt, L. V., Vega, S., Bazarni, J., and De Clercq, E., 1,1,3-Trioxo-2H,4H-thieno [e-3,4][1,2,4]thiadiazines (TTDs) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.Antimicrob. Agents. Chemother., 42, 618–623 (1998).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yan, RZ., Liu, XY., Xu, WF. et al. Synthesis and anti-HIV evaluation of the novel 2-(m-chlorobenzyl)-4-substituted-7-methyl-1, 1, 3-trioxo-pyrazolo[4, 5-e] [1, 2, 4]thiadiazines. Arch Pharm Res 29, 957–962 (2006). https://doi.org/10.1007/BF02969278
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02969278